MOWOOT · Project

Wearable Medical Device That Treats Chronic Constipation Without Drugs or Surgery

healthMarket-readyTRL 8

Imagine a belt-like device you wear on your belly that gently massages your abdomen the same way a trained physiotherapist would — except it does it automatically, every day, at home. It helps people with chronic constipation move things along naturally, no pills, no side effects. The company behind it already proved it works in clinical trials and built a production-ready version. They're targeting the 150 million people in Europe and the US who deal with this uncomfortable problem daily.

By the numbers

15%

Share of EU and USA population suffering from chronic constipation

150 million

People with chronic constipation in target markets

90 billion €

Estimated addressable market size

Below 500€

Target manufacturing cost per unit

2.5 M€

Expected EBITDA

50-100 units

Mowoot 2.0 prototypes produced

New specialized employees to be hired

TRL7

Technology readiness level at project start

The business problem

What needed solving

Chronic constipation affects up to 15% of the population in Europe and the US — roughly 150 million people — with the elderly, women, and patients with neurological conditions like Parkinson's and multiple sclerosis hit hardest. Current treatments rely heavily on laxatives and medications that come with side effects and don't address the root mechanical problem. Care facilities and patients need a drug-free, easy-to-use alternative that works at home without a therapist.

The solution

What was built

USMIMA built MOWOOT 2.0, a wearable Class II medical device that automatically performs abdominal massage to relieve chronic constipation. Deliverables included a midterm prototype batch (2-4 units) and a production prototype batch (50-100 units) of the upgraded Mowoot 2.0, which added cloud connectivity and smart services over the original version.

Audience

Who needs this

Nursing home and elder care facility operators managing constipation across resident populationsMedical device distributors looking for new home-care products in gastroenterologyNeurology and rehabilitation clinics treating Parkinson's, MS, and spinal cord injury patientsHome healthcare agencies providing non-pharmacological treatment optionsHealth insurance companies seeking cost-effective alternatives to long-term laxative prescriptions

Business applications

Who can put this to work

Elder care and nursing homes

any

Target: Residential care facility operators and nursing home chains

If you are an elder care provider dealing with chronic constipation among your residents — a problem affecting up to 15% of the population and far more among the elderly — this project developed MOWOOT, a wearable Class II medical device that automatically performs abdominal massage. It replaces daily laxative regimens with a drug-free alternative, reducing medication costs and improving resident comfort without requiring trained physiotherapist staff.

Home medical equipment distribution

mid-size

Target: Medical device distributors and home healthcare product retailers

If you are a medical device distributor looking for new products in the growing home-care segment — MOWOOT is a CE-marked Class II wearable device targeting a market the company estimates at 90 billion euros across 150 million sufferers. The device is manufactured at a target cost below 500€ per unit and is designed for direct patient use at home, making it ideal for prescription-based distribution channels.

Neurology and rehabilitation clinics

any

Target: Clinics specializing in Parkinson's disease, multiple sclerosis, or spinal cord injury rehabilitation

If you run a rehabilitation or neurology clinic where patients with Parkinson's, multiple sclerosis, or spinal cord injuries suffer from neurogenic bowel dysfunction — MOWOOT offers a non-invasive, drug-free treatment option. Clinical pilot studies showed it ameliorates chronic constipation, giving your patients better quality of life without adding to their already heavy medication load.

Frequently asked

Quick answers

What does the device cost and what is the expected price point?

The project objective states a target to reduce manufacturing costs below 500€ per unit through scaling production. This was the goal for the Mowoot 2.0 version. Final retail pricing would depend on distribution channel and market, but the sub-500€ production cost suggests a consumer price point accessible for home medical devices.

Can this be manufactured at industrial scale?

Yes. The project produced 50-100 units of the Mowoot 2.0 prototype, demonstrating small-batch manufacturing capability. One of the core Phase 2 objectives was specifically to scale the manufacturing process to reduce unit costs. The single-company consortium (USMIMA SL) is an SME focused entirely on this product.

What is the IP and licensing situation?

MOWOOT was developed entirely by USMIMA SL as the sole consortium partner under SME Instrument Phase 2 funding. This means IP ownership is concentrated in a single company. Any licensing or distribution partnership would need to be negotiated directly with USMIMA.

Is this device approved by regulators?

The project describes MOWOOT as a Class II medical device, indicating it has gone through the relevant EU medical device classification process. The company website (mowoot.com) is still active, suggesting continued commercial operations. Specific CE marking or FDA status would need to be confirmed directly with USMIMA.

What clinical evidence supports this device?

A pilot study with chronically constipated patients demonstrated that daily use of MOWOOT ameliorates idiopathic chronic constipation, reaching TRL7 before the Phase 2 project began. The Phase 2 objective included conducting a larger clinical study to build confidence in the medical sector and promote prescriptions.

How quickly could this be integrated into a care facility?

The device is designed for autonomous patient use at home, meaning it requires minimal training or clinical infrastructure. For care facilities, deployment would involve prescribing the device per patient. The Mowoot 2.0 version added cloud and smart services for potential remote monitoring capabilities.

Consortium

Who built it

This is a solo-company project — USMIMA SL from Spain is the only partner, which is typical for SME Instrument Phase 2 funding. The consortium is 100% industry with no universities or research organizations, meaning the technology is firmly in commercial development rather than academic research. As an SME, USMIMA holds all the IP and decision-making power, which simplifies any partnership or licensing discussions. The single-country, single-partner structure means there is one point of contact for business negotiations, but it also means the company carries all the risk and may be looking for distribution partners to scale into new markets.

How to reach the team

USMIMA SL is a Spanish SME — contact can be found through their website mowoot.com or via LinkedIn search for USMIMA leadership

Order a report on this consortium

Next steps

Talk to the team behind this work.

SciTransfer can facilitate a direct introduction to the MOWOOT team for distribution partnerships, clinical collaboration, or bulk procurement discussions.

Order a report on this topic More in Health & Biomedical